- Home
- BLUE
BLUE
bluebird bio Inc.
as 12-20-2024 4:00pm EST
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | 78.7M | IPO Year: | 2013 |
| Target Price: | $49.14 | AVG Volume (30 days): | 729.7K |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -33.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.80 - $38.40 | Next Earning Date: | 11-14-2024 |
| Revenue: | $53,120,000 | Revenue Growth: | 144.50% |
| Revenue Growth (this year): | 152.71% | Revenue Growth (next year): | 233.91% |
Stock Insider Trading Activity of bluebird bio Inc. (BLUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Colvin Richard A | BLUE | Chief Medical Officer | Dec 10 '24 | Sell | $0.42 | 2,824 | $1,178.46 | 165,544 | |
| Klima Thomas J | BLUE | See Remarks | Sep 30 '24 | Sell | $0.53 | 1,006 | $528.85 | 170,000 | |
| Obenshain Andrew | BLUE | President and CEO | Sep 30 '24 | Sell | $0.53 | 34,780 | $18,269.93 | 375,218 |
Latest bluebird bio Inc. News
BLUE Breaking Stock News: Dive into BLUE Ticker-Specific Updates for Smart Investing
Business Wire
14 days ago
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire
15 days ago
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Business Wire
18 days ago
bluebird bio Announces 1-for-20 Reverse Stock Split
Business Wire
18 days ago
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Benzinga
23 days ago
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
Simply Wall St.
a month ago
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Benzinga
a month ago
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
GuruFocus.com
a month ago
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
Compare BLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLUE bluebird bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.